Karyopharm Therapeutics Inc KPTI
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-11-06 |
| Shares Out. | 22,660,000 |
| Website | karyopharm.com/ ↗ |
| Phone | 13026587581 |
| Employees | 228 |
| Revenue | $33.4M |
| Gross Profit | $32.3M |
| Net Income | -$67.0M |
| Free Cash Flow | -$65.3M |
| Total Assets | $111.3M |
| Total Liabilities | $441.5M |
| Equity | -$330.2M |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Karyopharm Therapeutics Inc is a publicly traded company under the ticker symbol KPTI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)